Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: Pulmonary adenocarcinoma versus mesothelioma

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 2, 2007, Pages 140-144

  Marchevsky, Alberto M ^a   Wick, Mark R ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Evidence based medicine; Immunostains; Meta analysis; Practice guidelines; Statistics

Indexed keywords

ANTIBODY; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; NERVE CELL ADHESION MOLECULE; THROMBOMODULIN; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER DIAGNOSIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOHISTOLOGY; LUNG ADENOCARCINOMA; MALIGNANT MESOTHELIOMA; METASTASIS; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY;

ADENOCARCINOMA; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; ODDS RATIO; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34249661669     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213148.62525.9a     Document Type: Article

References (41)

1. Amin MB, Young RH. Introduction to immunohistochemistry in the diagnosis of genitourinary lesions. Seminars Diagn Pathol. 2005;22:1-2.
2. Battifora H. Mesothelioma versus carcinoma: getting easier? Hum Pathol. 2005;36:1153.
3. Battifora HA, Gown AM. Do we need two more mesothelial markers? Hum Pathol. 2005;36:451-452.
4. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29:747-754.
5. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol. 2001;116:246-252.
6. Vassallo J, Pinto GA. Antibody panel in diagnosis of lymphoid neoplasms. J Clin Pathol. 1998;51:638-639.
7. Ashby D, Smith AF. Evidence-based medicine as Bayesian decision-making. Stat Med. 2000;19:3291-3305.
8. Marchevsky AM, Wick MR. Evidence-based medicine, medical decision analysis, and pathology 2. Hum Pathol. 2004;35:1179-1188.
9. Sackett DL, Straus SE, Richardson WS, et al. Evidence-based Medicine. How to Practice and Teach EBM. London, United Kingdom: Churchill Livingstone; 2001.
10. Gross R, Jensen N. Using evidence to make decisions. WMJ. 1999;98:53-56.
11. Akobeng AK. Understanding systematic reviews and meta-analysis. Arch Dis Child. 2005;90:845-848.
12. Burgers JS, van Everdingen JJ. Beyond the evidence in clinical guidelines. Lancet. 2004;364:392-393.
13. Byers JF, Stullenbarger E. Meta-analysis and decision analysis bridge research and practice. West J Nurs Res. 2003;25:193-204.
14. Acton GJ. Meta-analysis: a tool for evidence-based practice. AACN Clin Issues. 2001;12:539-545.
15. Christakis DA. Systematic reviews: a critical first step. Arch Pediatr Adolesc Med. 2001;155:636.
16. Agrawal D. Inappropriate interpretation of the odds ratio: oddly not that uncommon 3. Pediatrics. 2005;116:1612-1613.
17. Siadaty MS, Shu J. Proportional odds ratio model for comparison of diagnostic tests in meta-analysis. BMC Med Res Methodol. 2004;4:27.
18. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519-523.
19. Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129-1135.
20. King JE, Thatcher N, Pickering CA, et al. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology. 2006;48:223-232.
21. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19:514-523.
22. Marchevsky AM, Shah S, Patel S. Reasoning with uncertainty in pathology: artificial neural networks and logistic regression as tools for prediction of lymph node status in breast cancer patients. Mod Pathol. 1999;12:505-513.
23. Singson RP, Alsabeh R, Geller SA, et al. Estimation of tumor stage and lymph node status in patients with colorectal adenocarcinoma using probabilistic neural networks and logistic regression. Mod Pathol. 1999;12:479-484.
24. Marchevsky AM, Patel S, Wiley KJ, et al. Artificial neural networks and logistic regression as tools for prediction of survival in patients with stages I and II non-small cell lung cancer 3. Mod Pathol. 1998;11:618-625.
25. Moreira T, May C, Mason J, et al. A new method of analysis enabled a better understanding of clinical practice guideline development processes. J Clin Epidemiol. 2006;59:1199-1206.
26. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407-1414.
27. King JE, Hasleton PS. Immunohistochemistry and the diagnosis of malignant mesothelioma. Histopathology. 2001;38:471-476.
28. Gross R. Decisions and Evidence in Medical Practice. St Louis, Missouri: Mosby; 2001.
29. Delahunt B, Eble JN, King D, et al. Immunohistochemical evidence for mesothelial origin of paratesticular adenomatoid tumour. Histopathology. 2000;36:109-115.
30. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005;36:372-380.
31. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-1428.
32. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051.
33. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol. 2002;33:953-967.
34. Keefe DM, Peterson DE, Schubert MM. Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls. Support Care Cancer. 2006;14:492-498.
35. Baumann MH, Gutterman DD. American College of Chest Physicians evidence-based guidelines - the next generation: considering resource use and evolution to a single grading system. Chest. 2006;129:10-12.
36. Doherty S. Evidence-based implementation of evidence-based guidelines. Int J Health Care Qual Assur Inc Leadersh Health Serv. 2006;19:32-41.
37. Oosterhuis WP, Bruns DE, Watine J, et al. Evidence-based guidelines in laboratory medicine: principles and methods. Clin Chem. 2004;50:806-818.
38. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-105.
39. Korolija D, Sauerland S, Wood-Dauphinee S, et al. Evaluation of quality of life after laparoscopic surgery: evidence-based guidelines of the European Association for Endoscopic Surgery. Surg Endosc. 2004;18:879-897.
40. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. Clin Med. 2001;1:478-484.
41. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-1055.